206 related articles for article (PubMed ID: 29538209)
1. The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis.
Gu ZC; Zhang YJ; Pan MM; Zhang C; Liu XY; Wei AH; Su YJ
Medicine (Baltimore); 2018 Mar; 97(11):e0122. PubMed ID: 29538209
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J
Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
6. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Cheng J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
[TBL] [Abstract][Full Text] [Related]
7. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Aversa M; Porter S; Granton J
Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
[TBL] [Abstract][Full Text] [Related]
9. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
Rubin LJ
Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
[TBL] [Abstract][Full Text] [Related]
10. [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
Batyraliev TA; Makhmutkhodzhaev SA; Ekinsi E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
Kardiologiia; 2007; 47(7):73-82. PubMed ID: 18260899
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
Duo-Ji MM; Long ZW
Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
[TBL] [Abstract][Full Text] [Related]
12. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
14. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
Ryerson CJ; Nayar S; Swiston JR; Sin DD
Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
17. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
Musch A
Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
[TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
Kuntz M; Leiva-Juarez MM; Luthra S
Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]